Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

Hiam Chemaitelly, PhD^{1,2,3*}, Houssein H. Ayoub, PhD⁴, Sawsan AlMukdad, MSc^{1,2}, Peter Coyle, MD^{5,6,7}, Patrick Tang, MD PhD⁸, Hadi M. Yassine, PhD^{6,9}, Hebah A. Al-Khatib, PhD^{6,9}, Maria K. Smatti, MSc^{6,9}, Mohammad R. Hasan, PhD⁸, Zaina Al-Kanaani, PhD⁵, Einas Al-Kuwari, MD⁵, Andrew Jeremijenko, MD⁵, Anvar Hassan Kaleeckal, MSc⁵, Ali Nizar Latif, MD⁵, Riyazuddin Mohammad Shaik, MSc⁵, Hanan F. Abdul-Rahim, PhD¹⁰, Gheyath K. Nasrallah, PhD^{6,9}, Mohamed Ghaith Al-Kuwari, MD¹¹, Adeel A. Butt, MBBS MS^{3,5,12}, Hamad Eid Al-Romaihi, MD¹³, Mohamed H. Al-Thani, MD¹³, Abdullatif Al-Khal, MD⁵, Roberto Bertollini, MD MPH¹³, and Laith J. Abu-Raddad, PhD^{1,2,3,10*}

¹Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar

²World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

³Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA

⁴Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar

⁵*Hamad Medical Corporation, Doha, Qatar*

Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar

⁷Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom

⁸Department of Pathology, Sidra Medicine, Doha, Qatar

⁹Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar

¹⁰Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar

¹¹Primary Health Care Corporation, Doha, Qatar

¹²Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York, USA

¹³Ministry of Public Health, Doha, Qatar

Word count: Abstract: 236 words, Main Text: 1,801 words.

Number of tables: 5.

Number of figures: 4.

Running head: mRNA vaccine effectiveness against Omicron subvariants

Keywords: COVID-19; vaccine; Omicron; variant; sub-lineage; case-control study; test-negative; epidemiology.

*Correspondence to Dr. Hiam Chemaitelly, E-mail: <u>hsc2001@qatar-med.cornell.edu</u> or Professor Laith J. Abu-Raddad, E-mail: <u>lja2002@qatar-med.cornell.edu</u>.

Abstract

The SARS-CoV-2 Omicron (B.1.1.529) variant has two subvariants, BA.1 and BA.2, that are genetically quite divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of mRNA COVID-19 vaccines, after the second dose and after a third/booster dose, against BA.1 and BA.2 infections in Qatar's population. BNT162b2 effectiveness against symptomatic BA.1 infection was highest at 46.6% (95% CI: 33.4-57.2%) in the first three months after the second dose, but then declined to $\sim 10\%$ or below thereafter. Effectiveness rapidly rebounded to 59.9% (95% CI: 51.2-67.0%) in the first month after the booster dose, but then started to decline again. BNT162b2 effectiveness against symptomatic BA.2 infection was highest at 51.7% (95% CI: 43.2-58.9%) in the first three months after the second dose, but then declined to $\sim 10\%$ or below thereafter. Effectiveness rapidly rebounded to 43.7% (95% CI: 36.5-50.0%) in the first month after the booster dose, but then declined again. Effectiveness against COVID-19 hospitalization and death was in the range of 70-80% any time after the second dose, and was greater than 90% after the booster dose. Similar patterns of protection were observed for the mRNA-1273 vaccine. mRNA vaccines provide only moderate and short-lived protection against symptomatic Omicron infections, with no discernable differences in protection against either the BA.1 or BA.2 subvariants. Vaccine protection against COVID-19 hospitalization and death is strong and durable after the second dose, but is more robust after a booster dose.

Introduction

Qatar endured a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529)¹ wave that started on December 19, 2021 and peaked in mid-January, 2022²⁻⁵. The wave was first dominated by the BA.1 Omicron subvariant, but within a few days, the BA.2 subvariant predominated (Figure 1). While BA.1 and BA.2 remain classified as subvariants of the Omicron variant, there is considerable genetic distance between them⁶. Accordingly, we investigated duration of protection of BNT162b2 (Pfizer-BioNTech)⁷ and mRNA-1273 (Moderna)⁸ mRNA coronavirus disease 2019 (COVID-19) vaccines, after the second dose and after the third/booster dose, against symptomatic BA.1 and BA.2 infections, between December 23, 2021 and February 28, 2022. Duration of vaccine protection was also investigated against any severe (acute-care hospitalization)⁹, critical (intensive-care-unit hospitalization)⁹, or fatal¹⁰ infection due to either Omicron subvariant.

Vaccine effectiveness was estimated using the test-negative, case-control study design^{11,12}, applying methodology that was developed earlier to assess duration of protection of the BNT162b2¹³ and mRNA-1273¹⁴ vaccines in the same population during pre-Omicron SARS-CoV-2 infection waves (Methods). Cases (persons infected with BA.1, BA.2, or any-Omicron-subvariant) and controls (uninfected persons) were exact-matched by sex, 10-year age group, nationality, and calendar week of polymerase chain reaction (PCR) test to control for established differences in the risk of exposure to SARS-CoV-2 infection in Qatar¹⁵⁻¹⁹.

Results

Main analyses

By February 28, 2022 (end of study), 1,308,926 individuals received 2 or more BNT162b2 doses, and 355,979 of these received a booster dose. Meanwhile, 894,142 individuals received 2 or more mRNA-1273 doses, and 146,961 of these received a booster dose. The median dates of first, second, and third doses were May 3, 2021, May 24, 2021, and December 27, 2021 for BNT162b2; and May 28, 2021, June 27, 2021, and January 16, 2022 for mRNA-1273, respectively. The median time between the first and second doses was 21 days (interquartile range (IQR), 21-22 days) for BNT162b2 and 28 days (IQR, 28-30 days) for mRNA-1273. The median time between the second and booster doses was 251 days (IQR, 233-275 days) for BNT162b2 and 236 days (IQR, 213-261 days) for mRNA-1273.

The process used to select the study populations is shown in Figure 2. Demographic characteristics of the study populations are presented in Tables 1 and 2. The study was conducted based on the total population of Qatar. The study populations are therefore representative of the internationally diverse, but predominantly young and male population of Qatar.

BNT162b2 effectiveness against symptomatic BA.1 infection was highest at 46.6% (95% confidence interval (CI): 33.4-57.2%) in the first three months after the second dose, but then declined to ~10% or below thereafter (Figure 3A and Table 3). Effectiveness rapidly rebounded to 59.9% (95% CI: 51.2-67.0%) in the first month after the booster dose, but then declined to 40.5% (95% CI: 30.8-48.8%) in the second month and thereafter (only a small proportion of individuals were in the third or more months after the booster dose). A similar pattern was observed for mRNA-1273 effectiveness (Figure 3B and Table 4).

BNT162b2 effectiveness against symptomatic BA.2 infection was highest at 51.7% (95% CI: 43.2-58.9%) in the first three months after the second dose, but then declined to ~10% or below thereafter (Figure 3C and Table 3). Effectiveness rapidly rebounded to 43.7% (95% CI: 36.5-

4

50.0%) in the first month after the booster dose, but then declined to 40.2% (95% CI: 34.2-45.7%) in the second month and thereafter. A similar pattern was observed for mRNA-1273 effectiveness (Figure 3D and Table 4).

BNT162b2 effectiveness against any symptomatic Omicron infection, regardless of subvariant, was highest at 47.8% (95% CI: 40.8-53.9%) in the first three months after the second dose, but then declined to ~15% or below thereafter (Figure 4A and Table 3). Effectiveness rapidly rebounded to 49.5% (95% CI: 44.3-54.1%) in the first month after the booster dose, but then declined to 39.4% (95% CI: 34.4-44.0%) in the second month and thereafter. A similar pattern was observed for mRNA-1273 effectiveness (Figure 4B and Table 4).

Effectiveness against any severe, critical, or fatal COVID-19 due to an Omicron infection, regardless of subvariant, was in the range of 70-80% at any time after the second dose for both the BNT162b2 and mRNA-1273 vaccines (Figures 4C and 4D and Table 5). However, BNT162b2 effectiveness against any severe, critical, or fatal COVID-19 after the booster dose was greater than 90%. 95% CIs around estimates of mRNA-1273 effectiveness against any severe, critical, or fatal COVID-19 after the booster dose here were too few hospitalized COVID-19 cases among mRNA-1273 vaccinated persons (Table 5).

Additional analyses

Sensitivity analyses adjusting for documented prior infection and healthcare worker status yielded similar findings to the main analyses (Supplementary Tables 1 and 2). Sensitivity analyses to assess the impact of excluding children <12 years of age (Supplementary Tables 3 and 4), or individuals <20 years of age (Supplementary Tables 5 and 6), also yielded similar findings to the main analyses.

Discussion

No discernable differences were observed in the duration of mRNA vaccine protection against BA.1 versus BA.2 symptomatic infection. For each of these subvariants, vaccine effectiveness against symptomatic infection was ~50% in the first three months after the second dose, but declined to negligible levels thereafter. Effectiveness rapidly rebounded after the booster dose to reach similar levels to those seen right after the second dose, but appeared to wane again starting from the second month after the booster dose. There were also no discernable differences in effectiveness of BNT162b2 vaccine versus mRNA-1273 vaccine.

Despite only moderate and rapidly waning protection against symptomatic infection, mRNA vaccine effectiveness against COVID-19 hospitalization and death due to Omicron infections was strong at greater than 70% after the second dose. It was also higher after the booster dose at greater than 90%. These findings support the durability of vaccine protection against COVID-19 hospitalization and death for at least several months after receiving the second dose,^{13,14} but also demonstrate the importance of booster vaccination in achieving robust protection against any hospitalization and death due to Omicron infections. These findings suggest the need to consider rapid implementation of booster vaccination campaigns coincident with the emergence of a new wave or variant, at least to those most vulnerable to COVID-19 hospitalization and death.

This study has limitations. With the lower severity of Omicron infections²⁰ and the young population of Qatar^{15,21}, case numbers were insufficient to estimate the duration of protection against COVID-19 hospitalization and death for each subvariant separately. BA.1 and BA.2 ascertainment was based on proxy criteria, presence or absence of an S-gene "target failure" using the TaqPath PCR assay (Methods), but this method of ascertainment is well established not only for Omicron subvariants, but also for other variants such as Alpha²²⁻²⁴. Some Omicron

6

infections may have been misclassified Delta infections, but this is not likely, as Delta incidence was limited during the study duration (Methods).

Vaccine protection was assessed for only several months after the second dose, and only several weeks after the booster dose. Longer-term protection against symptomatic infection and COVID-19 hospitalization and death remain uncertain. Vaccine effectiveness reached small but statistically significant negative values at 7 months or more after the second dose. Negative estimated effectiveness likely reflects an effect of bias and not true negative biological effectiveness. This bias may have risen from vaccinated persons having a higher social contact rate or adhering less to safety measures than unvaccinated persons²⁵⁻²⁷. With the high vaccine coverage among adults in Qatar $(>85\%)^{13}$, this bias may have also risen because the reference group of unvaccinated individuals included mainly children or young persons; therefore, it may not be representative of the wider population. However, sensitivity analyses excluding children and young persons confirmed the same study findings (Supplementary Tables 3-6). Unvaccinated adults are a small minority that may not be truly immune-naïve due to undocumented prior SARS-CoV-2 infections, especially now that we are two years into this pandemic. Bias due to depletion of the susceptible population may lead to underestimation of vaccine effectiveness²⁸, even in the test-negative, case-control, study design, which is less prone to effect of this bias¹³.

While matching was done for sex, age, and nationality, this was not possible for other factors, such as comorbidities, as such data are not available. However, matching by these factors provided demonstrable control of bias in studies of different epidemiologic designs and that used control groups in Qatar^{13,14,29-31}. Effectiveness was assessed using an observational, test-negative, case-control, study design^{11,12}, rather than a design in which cohorts of vaccinated and

7

unvaccinated individuals were followed up. However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case-control design^{30,32,33}, supporting the validity of this standard approach in assessing vaccine effectiveness^{11,12,30,34}. Moreover, our recent study of the effectiveness of booster vaccination against any symptomatic Omicron infection, relative to that of the primary series, used a cohort study design⁵ and its results are consistent with results generated in the present study using the test-negative, case-control study design.

Nonetheless, one cannot exclude the possibility that in real-world data, bias could arise in unexpected ways, or from unknown sources, such as subtle differences in test-seeking behavior or changes in the pattern of testing with introduction of other testing modalities, such as rapid antigen testing (RAT). For example, with the large Omicron wave in Qatar, use of RAT was expanded to supplement PCR testing starting from January 5, 2022. However, RAT was broadly implemented in the population and probably did not differentially affect PCR testing to introduce bias. With the small proportion of Qatar's population \geq 50 years of age^{15,35}, our findings may not be generalizable to other countries in which elderly citizens constitute a larger proportion of the total population.

Notwithstanding these limitations, consistent findings were reached, indicating rapid waning of vaccine protection against symptomatic Omicron infection that are consistent with findings of other studies for effectiveness against Omicron infection (with no BA.1/BA.2 subvariant specified)³⁶⁻⁴¹. Moreover, with the mass scale of PCR testing in Qatar¹³, the likelihood of bias is perhaps minimized. Extensive sensitivity and additional analyses were conducted to investigate effects of potential bias in our earlier studies for the BNT162b2¹³ and mRNA-1273¹⁴ vaccines, which used the same methodology used here. These included different adjustments in the

analysis, different approaches for factoring prior infection in the analysis, and different study inclusion and exclusion criteria to investigate whether effectiveness estimates could have been biased^{13,14}. These analyses showed consistent findings^{13,14}.

In conclusion, mRNA vaccines provide only moderate protection against symptomatic BA.1 and

BA.2 Omicron infections, with no discernable differences in protection against either the BA.1

or BA.2 subvariants. Protection also wanes rapidly to negligible levels, starting four months after the second dose. Vaccine protection rebounds after booster vaccination, but also appears to wane thereafter. Meanwhile, vaccine protection against COVID-19 hospitalization and death is strong and durable after the second dose, and is most robust after a booster dose.

Acknowledgements

We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, the Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine – Qatar for their diligent efforts and contributions to make this study possible. The authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. Statements made herein are solely the responsibility of the authors. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article.

Author contributions

HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. PT and MRH conducted the multiplex, RT-qPCR variant screening and viral genome sequencing. HY, HAK, and MKS conducted viral genome sequencing. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript.

Competing interests

Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests.

References

- 1. World Health Organization. Tracking SARS-CoV-2 variants. Available from: <u>https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</u>. (2021).
- 2. National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. https://www.gisaid.org/phylodynamics/global/nextstrain/. (2021).
- 3. Altarawneh, H.N., *et al.* Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. *N Engl J Med* (2022).
- 4. Chemaitelly, H., *et al.* Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. *medRxiv*, 2022.2002.2024.22271440 (2022).
- 5. Abu-Raddad, L.J., *et al.* Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. *New England Journal of Medicine* (2022).
- 6. Kumar, S., Karuppanan, K. & Subramaniam, G. Omicron (BA.1) and Sub-Variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative Sequence and Structural-based Computational Assessment. *bioRxiv*, 2022.2002.2011.480029 (2022).
- 7. Polack, F.P., *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **383**, 2603-2615 (2020).
- 8. Baden, L.R., *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **384**, 403-416 (2021).
- 9. World Health Organization. COVID-19 clinical management: living guidance. Available from: <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1</u>. Accessed on: May 31, 2021. (2021).
- World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available from: <u>https://www.who.int/classifications/icd/Guidelines Cause of Death COVID-19-</u> <u>20200420-EN.pdf?ua=1</u>. Document Number: WHO/HQ/DDI/DNA/CAT. Accessed on May 31, 2021. (2021).
- 11. Jackson, M.L. & Nelson, J.C. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine* **31**, 2165-2168 (2013).
- 12. Verani, J.R., *et al.* Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. *Vaccine* **35**, 3295-3302 (2017).
- 13. Chemaitelly, H., *et al.* Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med* **385**, e83 (2021).
- 14. Abu-Raddad, L.J., Chemaitelly, H., Bertollini, R. & National Study Group for Covid Vaccination. Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar. *N Engl J Med* (2022).
- 15. Abu-Raddad, L.J., *et al.* Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. *Sci Rep* **11**, 6233 (2021).
- 16. Ayoub, H.H., *et al.* Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. *J Glob Health* **11**, 05005 (2021).
- 17. Coyle, P.V., *et al.* SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. *iScience* **24**, 102646 (2021).

- 18. Al-Thani, M.H., *et al.* SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. *Open Forum Infect Dis* **8**, ofab221 (2021).
- 19. Jeremijenko, A., *et al.* Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. *Emerg Infect Dis* **27**, 1343-1352 (2021).
- 20. Wolter, N., *et al.* Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. *Lancet* **399**, 437-446 (2022).
- 21. Seedat, S., *et al.* SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. *Sci Rep* **11**, 18182 (2021).
- 22. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 34. (England, 2022).
- 23. Abu-Raddad, L.J., *et al.* Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. *PLoS Med* **18**, e1003879 (2021).
- 24. Challen, R., *et al.* Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* **372**, n579 (2021).
- 25. Makhoul M., *et al.* Epidemiological impact of SARS-CoV-2 vaccination: Mathematical modeling analyses. *Vaccines* **8**(2020).
- 26. Usherwood, T., LaJoie, Z. & Srivastava, V. A model and predictions for COVID-19 considering population behavior and vaccination. *Scientific Reports* **11**, 12051 (2021).
- Andersson, O., Campos-Mercade, P., Meier, A.N. & Wengström, E. Anticipation of COVID-19 Vaccines Reduces Social Distancing. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3765329. SSRN (2021).
- 28. Ray, G.T., *et al.* Depletion-of-susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness. *Clin Infect Dis* **70**, 1484-1486 (2020).
- 29. Abu-Raddad, L.J., *et al.* Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. *J Travel Med* **28**(2021).
- 30. Chemaitelly, H., *et al.* mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* **27**, 1614-1621 (2021).
- 31. Abu-Raddad, L.J., Chemaitelly, H., Bertollini, R. & National Study Group for Covid Vaccination. Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar. *N Engl J Med* (2022).
- 32. Abu-Raddad, L.J., Chemaitelly, H., Butt, A.A. & National Study Group for Covid Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* **385**, 187-189 (2021).
- 33. Butt, A.A., *et al.* SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. *J Clin Invest* **131**(2021).
- 34. Lopez Bernal, J., *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* **385**, 585-594 (2021).
- 35. Planning and Statistics Authority-State of Qatar. Qatar Monthly Statistics. Available from: <u>https://www.psa.gov.qa/en/pages/default.aspx</u>. Accessed on: May 26, 2020. (2020).
- 36. Andrews, N., *et al.* Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *New England Journal of Medicine* (2022).
- 37. Buchan, S.A., *et al.* Effectiveness of COVID-19 vaccines against Omicron or Delta infection. *medRxiv*, 2021.2012.2030.21268565 (2022).

- 38. Hansen, C.H., *et al.* Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. *medRxiv*, 2021.2012.2020.21267966 (2021).
- 39. Patalon, T., *et al.* Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine. *medRxiv*, 2022.2002.2025.22271494 (2022).
- 40. Šmíd, M., *et al.* Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2. *medRxiv*, 2022.2002.2024.22271396 (2022).
- 41. Tseng, H.F., *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. *medRxiv*, 2022.2001.2007.22268919 (2022).
- 42. Vogels, C., Fauver, J. & Grubaugh, N. Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V.3. dx.doi.org/10.17504/protocols.io.br9vm966. (2021).
- 43. Benslimane, F.M., *et al.* One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar. *Front Cell Infect Microbiol* **11**, 768883 (2021).
- 44. Hasan, M.R., *et al.* Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. *Int J Infect Dis* **112**, 52-54 (2021).
- 45. Saththasivam, J., *et al.* COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar. *Sci Total Environ* **774**, 145608 (2021).
- 46. Thermo Fisher Scientific. TaqPath[™] COVID-19 CE-IVD RT-PCR Kit instructions for use. Available from: <u>https://assets.thermofisher.com/TFS-</u> <u>Assets/LSG/manuals/MAN0019215_TaqPathCOVID-19_CE-IVD_RT-</u> PCR%20Kit_IFU.pdf. Accessed on December 02, 2020. (2020).
- 47. Austin, P.C. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. *Communications in Statistics Simulation and Computation* **38**, 1228-1234 (2009).
- 48. Jacoby, P. & Kelly, H. Is it necessary to adjust for calendar time in a test negative design?: Responding to: Jackson ML, Nelson JC. The test negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31(April (17)):2165-8. *Vaccine* **32**, 2942 (2014).
- 49. Pearce, N. Analysis of matched case-control studies. *BMJ* 352, i969 (2016).
- 50. Rothman, K.J., Greenland, S. & Lash, T.L. *Modern epidemiology*, (Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, 2008).
- 51. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC. (2021).





Figure 1. Proportion of Omicron infections with the BA.1 (versus BA.2) subvariant in PCR-positive tests assessed using TaqPath COVID-19 Combo Kit during the study period.

Figure 2. Flowchart describing the population selection process for investigating effectiveness of the BNT162b2 and mRNA-1273 vaccines during the SARS-CoV-2 Omicron infection wave.



*A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

*Infected individuals were matched by sex, 10-year age group, nationality, and calendar week of PCR test to PCR-negative tests of uninfected individuals.

Note: In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated (our reference group). Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

Table 1. Demographic characteristics of cases and controls in samples used to estimate effectiveness of the BNT162b2 vaccine
against symptomatic SARS-CoV-2 BA.1 Omicron infection, symptomatic BA.2 Omicron infection, and any symptomatic
Omicron infection. The table was generated by combining the matched samples of the various time-since-vaccination strata.

		nst symptomatic SA Omicron infection	RS-CoV-2		Effectiveness against symptomatic SARS-CoV-2 BA.2 Omicron infection			inst any symptomati Omicron infection	c SARS-
Characteristics	Cases*	Controls [*]		Cases [‡]	Controls [‡]		Cases [§]	Controls [§]	
	(PCR-positive)	(PCR-negative)	SMD^{\dagger}	(PCR-positive)	(PCR-negative)	\mathbf{SMD}^{\dagger}	(PCR-positive)	(PCR-negative)	SMD^{\dagger}
	N=7,072	N=12,278		N=21,541	N=21,541		N=39,855	N=23,814	
Median age (IQR) — years	32 (22-42)	32 (20-42)	0.06¶	32 (18-42)	31 (18-42)	0.01¶	32 (19-42)	32 (19-43)	0.01¶
Age group — no. (%)									
<10 years	670 (9.5)	1,282 (10.4)		3,157 (14.7)	3,157 (14.7)		5,581 (14.0)	3,501 (14.7)	
10-19 years	875 (12.5)	1,611 (13.1)		2,458 (11.4)	2,458 (11.4)		4,594 (11.5)	2,640 (11.1)	
20-29 years	1,385 (19.7)	2,389 (19.5)		4,016 (18.6)	4,016 (18.6)		7,344 (18.4)	4,369 (18.4)	
30-39 years	1,983 (28.2)	3,487 (28.4)	0.05	5,561 (25.8)	5,561 (25.8)	0.00	10,419 (26.1)	6,066 (25.5)	0.03
40-49 years	1,053 (15.0)	1,782 (14.5)	0.05	2,824 (13.1)	2,824 (13.1)	0.00	5,462 (13.7)	3,254 (13.7)	0.05
50-59 years	674 (9.6)	1,115 (9.1)		2,166 (10.1)	2,166 (10.1)		3,995 (10.0)	2,440 (10.3)	
60-69 years	279 (4.0)	436 (3.6)		951 (4.4)	951 (4.4)		1,685 (4.2)	1,050 (4.4)	
70+ years	103 (1.5)	176 (1.4)		408 (1.9)	408 (1.9)		775 (1.9)	494 (2.1)	
Sex									
Male	3,437 (49.0)	6,335 (51.6)	0.05	11,986 (55.6)	11,986 (55.6)	0.00	21,951 (55.1)	13,257 (55.7)	0.01
Female	3,585 (51.1)	5,943 (48.4)	0.03	9,555 (44.4)	9,555 (44.4)	0.00	17,904 (44.9)	10,557 (44.3)	0.01
Nationality ^{**}									
Bangladeshi	102 (1.5)	184 (1.5)		521 (2.4)	521 (2.4)		872 (2.2)	614 (2.6)	
Egyptian	416 (5.9)	723 (5.9)		1,384 (6.4)	1,384 (6.4)		2,360 (5.9)	1,343 (5.6)	
Filipino	761 (10.8)	1,357 (11.1)		2,063 (9.6)	2,063 (9.6)		3,844 (9.6)	2,227 (9.4)	
Indian	793 (11.3)	1,467 (12.0)		3,077 (14.3)	3,077 (14.3)		5,403 (13.6)	3,314 (13.9)	
Nepalese	80 (1.1)	138 (1.1)	0.05	430 (2.0)	430 (2.0)	0.00	632 (1.6)	369 (1.6)	0.06
Pakistani	152 (2.2)	279 (2.3)	0.03	788 (3.7)	788 (3.7)	0.00	1,325 (3.3)	805 (3.4)	0.00
Qatari	2,824 (40.2)	5,074 (41.3)		7,277 (33.8)	7,277 (33.8)		14,632 (36.7)	8,304 (34.9)	
Sri Lankan	62 (0.9)	105 (0.9)		299 (1.4)	299 (1.4)		497 (1.3)	313 (1.3)	
Sudanese	328 (4.7)	576 (4.7)		1,036 (4.8)	1,036 (4.8)		1,730 (4.3)	1,026 (4.3)	
Other nationalities	1,504 (21.4)	2,375 (19.3)		4,666 (21.7)	4,666 (21.7)		8,560 (21.5)	5,499 (23.1)	

Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction; SMD, standardized mean difference. *Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

*SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates adequate matching.

[‡]Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

[§]Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

¹SMD is for the mean difference between groups divided by the pooled standard deviation. ^{**}Nationalities were chosen to represent the most populous groups in Qatar.

Table 2. Demographic characteristics of cases and controls in samples used to estimate effectiveness of the mRNA-1273 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, symptomatic BA.2 Omicron infection, and any symptomatic Omicron infection. The table was generated by combining the matched samples of the various time-since-vaccination strata.

		nst symptomatic SAI Omicron infection	RS-CoV-2		inst symptomatic SA Omicron infection	RS-CoV-2		inst any symptomat Omicron infection	ic SARS-
Characteristics	Cases*	Controls [*]		Cases [‡]	Controls [‡]		Cases [§]	Controls [§]	
	(PCR-positive)	(PCR-negative)	\mathbf{SMD}^{\dagger}	(PCR-positive)	(PCR-negative)	\mathbf{SMD}^{\dagger}	(PCR-positive)	(PCR-negative)	\mathbf{SMD}^{\dagger}
	N=3,574	N=6,176		N=13,537	N=13,537		N=21,810	N=13,288	
Median age (IQR) — years	30 (15-38)	29 (11-38)	0.07¶	28 (10-37)	28 (10-38)	0.01¶	28 (9-37)	28 (9-38)	0.00¶
Age group — no. (%)									
<10 years	670 (18.8)	1,282 (20.8)		3,149 (23.3)	3,149 (23.3)		5,576 (25.6)	3,496 (26.3)	
10-19 years	300 (8.4)	549 (8.9)		1,475 (10.9)	1,475 (10.9)		1,692 (7.8)	993 (7.5)	
20-29 years	771 (21.6)	1,286 (20.8)		2,633 (19.5)	2,633 (19.5)		4,311 (19.8)	2,608 (19.6)	
30-39 years	1,037 (29.0)	1,788 (29.0)	0.07	3,427 (25.3)	3,427 (25.3)	0.00	5,692 (26.1)	3,368 (25.4)	0.02
40-49 years	475 (13.3)	797 (12.9)	0.07	1,512 (11.2)	1,512 (11.2)	0.00	2,575 (11.8)	1,568 (11.8)	0.03
50-59 years	231 (6.5)	349 (5.7)		880 (6.5)	880 (6.5)		1,346 (6.2)	853 (6.4)	
60-69 years	68 (1.9)	89 (1.4)		315 (2.3)	315 (2.3)		400 (1.8)	261 (2.0)	
70+ years	22 (0.6)	36 (0.6)		146 (1.1)	146 (1.1)		218 (1.0)	141 (1.1)	
Sex									
Male	1,769 (49.5)	3,232 (52.3)	0.06	7,717 (57.0)	7,717 (57.0)	0.00	12,678 (58.1)	7,745 (58.3)	0.00
Female	1,805 (50.5)	2,944 (47.7)	0.00	5,820 (43.0)	5,820 (43.0)	0.00	9,132 (41.9)	5,543 (41.7)	0.00
Nationality ^{**}									
Bangladeshi	74 (2.1)	132 (2.1)		443 (3.3)	443 (3.3)		762 (3.5)	547 (4.1)	
Egyptian	224 (6.3)	393 (6.4)		897 (6.6)	897 (6.6)		1,249 (5.7)	715 (5.4)	
Filipino	524 (14.7)	890 (14.4)		1,402 (10.4)	1,402 (10.4)		2,396 (11.0)	1,389 (10.5)	
Indian	535 (15.0)	1,007 (16.3)		2,256 (16.7)	2,256 (16.7)		3,719 (17.1)	2,306 (17.4)	
Nepalese	74 (2.1)	132 (2.1)	0.07	431 (3.2)	431 (3.2)	0.00	625 (2.9)	363 (2.7)	0.06
Pakistani	118 (3.3)	221 (3.6)	0.07	658 (4.9)	658 (4.9)	0.00	1,042 (4.8)	633 (4.8)	0.00
Qatari	866 (24.2)	1,554 (25.2)		3,364 (24.9)	3,364 (24.9)		5,117 (23.5)	2,955 (22.2)	
Sri Lankan	42 (1.2)	74 (1.2)		262 (1.9)	262 (1.9)		444 (2.0)	271 (2.0)	
Sudanese	212 (5.9)	385 (6.2)		789 (5.8)	789 (5.8)		1,273 (5.8)	758 (5.7)	
Other nationalities	905 (25.3)	1,388 (22.5)		3,035 (22.4)	3,035 (22.4)		5,183 (23.8)	3,351 (25.2)	

Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction; SMD, standardized mean difference.

*Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

[†]SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates adequate matching.


*Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

[§]Cases and controls were matched two-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

¹SMD is for the mean difference between groups divided by the pooled standard deviation.

**Nationalities were chosen to represent the most populous groups in Qatar.

Figure 3. Effectiveness of the BNT162b2 and mRNA-1273 vaccines against symptomatic SARS-CoV-2 BA.1 Omicron infection (panels A and B, respectively) and symptomatic SARS-CoV-2 BA.2 Omicron infection (panels C and D, respectively). Data are presented as effectiveness point estimates. Error bars indicate the corresponding 95% confidence intervals.



Sub-studies [†]		Cases -positive)		ntrols negative)	Effectiveness in % (95% CI) [‡]						
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	(95% CI)*						
Effectiveness against symptomatic BA.1 Omicron infection [§]											
Dose 1											
0-13 days after Dose 1 and no Dose 2	10	1,969	20	3,456	23.5 (-70.6 to 65.7)						
\geq 14 days after Dose 1 and no Dose 2	25	1,968	66	3,441	39.2 (2.3 to 62.1)						
Dose 2											
1-3 months after Dose 2 and no Dose 3	130	1,992	376	3,409	46.6 (33.4 to 57.2)						
4-6 months after Dose 2 and no Dose 3	502	2,004	941	3,506	8.8 (-4.1 to 20.1)						
\geq 7 months after Dose 2 and no Dose 3	3,570	2,060	6,007	3,947	-17.8 (-28.2 to -8.2)						
Dose 3 (booster dose)											
<1 month after Dose 3	180	2,008	622	3,339	59.9 (51.2 to 67.0)						
≥1 month after Dose 3	483	2,031	1,145	3,441	40.5 (30.8 to 48.8)						
Effectiveness against symptomatic BA.2 Om	icron infection	1									
Dose 1											
0-13 days after Dose 1 and no Dose 2	32	5,744	34	5,742	5.9 (-52.5 to 41.9)						
≥14 days after Dose 1 and no Dose 2	64	5,774	99	5,739	36.1 (12.1 to 53.5)						
Dose 2											
1-3 months after Dose 2 and no Dose 3	263	5,964	496	5,731	51.7 (43.2 to 58.9)						
4-6 months after Dose 2 and no Dose 3	1,203	5,924	1,318	5,809	12.4 (3.8 to 20.3)						
\geq 7 months after Dose 2 and no Dose 3	8,003	5,840	7,762	6,081	-12.1 (-19.1 to -5.5)						
Dose 3 (booster dose)											
<1 month after Dose 3	709	6,038	1,034	5,713	43.7 (36.5 to 50.0)						
≥1 month after Dose 3	1,580	6,211	2,029	5,762	40.2 (34.2 to 45.7)						
Effectiveness against any symptomatic Omic	cron infection**										
Dose 1											
0-13 days after Dose 1	56	12,174	34	7,278	9.5 (-39.8 to 41.3)						
≥14 days after Dose 1 and no Dose 2	151	12,205	130	7,276	31.4 (12.5 to 46.3)						
Dose 2											
1-3 months after Dose 2 and no Dose 3	585	12,623	599	7,309	47.8 (40.8 to 53.9)						
4-6 months after Dose 2 and no Dose 3	2,479	12,590	1,605	7,333	16.3 (9.7 to 22.5)						
\geq 7 months after Dose 2 and no Dose 3	16,435	12,564	9,073	7,637	-9.0 (-14.5 to -3.7)						
Dose 3 (booster dose)											
<1 month after Dose 3	1,326	12,777	1,300	7,275	49.5 (44.3 to 54.1)						
≥1 month after Dose 3	3,120	13,040	2,484	7,360	39.4 (34.4 to 44.0)						

Table 3. Effectiveness of the BNT162b2 vaccine against symptomatic SARS-CoV-2 BA.1 **Omicron infection, BA.2 Omicron infection, and any Omicron infection*.**

*A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those

unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-

since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses.

[‡]Vaccine effectiveness was estimated using the test-negative, case-control study design^{11,12}.

[§]Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

Sub-studies [†]	-	Cases -positive)		ntrols negative)	Effectiveness in % (95% CI) [‡]						
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	(95% CI)*						
Effectiveness against symptomatic BA.1 Omicron infection [§]											
Dose 1											
0-13 days after Dose 1 and no Dose 2	3	1,942	8	3,400	50.0 (-91.3 to 86.9)						
\geq 14 days after Dose 1 and no Dose 2	14	1,942	19	3,405	-16.8 (-137.8 to 42.6)						
Dose 2											
1-3 months after Dose 2 and no Dose 3	6	1,943	27	3,396	71.0 (24.0 to 89.0)						
4-6 months after Dose 2 and no Dose 3	289	1,976	667	3,377	31.3 (19.1 to 41.7)						
\geq 7 months after Dose 2 and no Dose 3	1,125	1,999	1,847	3,638	-10.2 (-23.1 to 1.3)						
Dose 3 (booster dose)											
<1 month after Dose 3	55	1,951	182	3,377	51.5 (32.3 to 65.2)						
≥1 month after Dose 3	36	1,953	102	3,396	45.3 (17.8 to 63.5)						
Effectiveness against symptomatic BA.2 Om	icron infection	1									
Dose 1											
0-13 days after Dose 1 and no Dose 2	8	5,651	10	5,649	20.0 (-102.7 to 68.4)						
≥14 days after Dose 1 and no Dose 2	31	5,645	27	5,649	-15.4 (-95.1 to 31.8)						
Dose 2											
1-3 months after Dose 2 and no Dose 3	26	5,664	40	5,650	35.9 (-5.9 to 61.2)						
4-6 months after Dose 2 and no Dose 3	989	5,756	1,059	5,686	9.9 (-0.3 to 19.0)						
\geq 7 months after Dose 2 and no Dose 3	2,917	5,627	2,686	5,858	-20.4 (-30.2 to -11.2)						
Dose 3 (booster dose)											
<1 month after Dose 3	164	5,727	250	5,641	39.4 (24.8 to 51.2)						
≥1 month after Dose 3	92	5,709	149	5,652	41.9 (23.4 to 56.0)						
Effectiveness against any symptomatic Omic	cron infection**										
Dose 1											
0-13 days after Dose 1 and no Dose 2	17	11,987	11	7,153	9.8 (-94.1 to 58.1)						
≥14 days after Dose 1 and no Dose 2	52	11,984	36	7,150	9.5 (-39.9 to 41.5)						
Dose 2											
1-3 months after Dose 2 and no Dose 3	47	12,014	51	7,151	43.2 (15.0 to 62.1)						
4-6 months after Dose 2 and no Dose 3	1,863	12,321	1,294	7,205	18.7 (11.3 to 25.5)						
\geq 7 months after Dose 2 and no Dose 3	5,820	12,144	3,112	7,374	-13.7 (-21.3 to -6.6)						
Dose 3 (booster dose)											
<1 month after Dose 3	323	12,156	321	7,148	43.6 (33.2 to 52.4)						
≥1 month after Dose 3	169	12,100	181	7,155	47.5 (34.1 to 58.1)						

Table 4. Effectiveness of the mRNA-1273 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, BA.2 Omicron infection, and any Omicron infection^{*}.

*A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

[†]In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those


unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses.

[‡]Vaccine effectiveness was estimated using the test-negative, case-control study design^{11,12}.

Scases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

Figure 4. Effectiveness of the BNT162b2 and mRNA-1273 vaccines against any symptomatic SARS-CoV-2 Omicron infection regardless of subvariant (panels A and B, respectively) and against any severe⁹, critical⁹, or fatal¹⁰ COVID-19 due to an Omicron infection (panels C and D, respectively). Data are presented as effectiveness point estimates. Error bars indicate the corresponding 95% confidence intervals.



The negative lower bound for the confidence interval was truncated for the estimate at 1-6 weeks after Dose 3 in panel D, because the confidence interval was too wide.

			BNT	162b2				ml	RNA-1273	
Sub-studies*	Cas (Severe, c fatal di	ritical, or		trols [†] legative)	Effectiveness in %	Cas (Severe, cr fatal dis	ritical, or		Controls [†] CR-negative)	Effectiveness in %
	Vacci	nated	Vacci	inated	(95% CI) [§]	Vaccia	nated	V	accinated	(95% CI) [§]
	Yes	No	Yes	No		Yes	No	Yes	No	
Dose 1										
Dose 1 and no Dose 2	2	111	8	290	40.9 (-199.1 to 88.3)	0	110	3	287	100.0 (Omitted) [¶]
Dose 2										
1-6 months after Dose 2 and no Dose 3	14	123	108	261	70.4 (45.0 to 84.0)	2	113	34	272	87.1 (40.2 to 97.2)
\geq 7 months after Dose 2 and no Dose 3	76	143	461	218	77.5 (67.8 to 84.3)	23	126	148	264	68.4 (46.1 to 81.5)
Dose 3 (booster dose)										
1-6 weeks after Dose 3	8	125	143	257	90.9 (78.6 to 96.1)	1	110	18	280	81.8 (-49.5 to 97.8)
≥7 weeks after Dose 3	12	134	197	254	90.1 (80.6 to 95.0)	0	110	3	287	100.0 (Omitted) [¶]

Table 5. Effectiveness of the BNT162b2 and mRNA-1273 vaccines against any severe⁹, critical⁹, or fatal¹⁰ COVID-19.

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

*In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

[†]Cases and controls were matched one-to-five by sex, 10-year age group, nationality, and calendar week of PCR test.

[‡]Severity⁹, criticality⁹, and fatality¹⁰ were defined as per World Health Organization guidelines.

[§]Vaccine effectiveness was estimated using the test-negative, case-control study design^{11,12}.

Confidence interval could not be estimated using conditional logistic regression because of zero events among those vaccinated.

Methods

Oversight

Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with waiver of informed consent. The study was reported following the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines. The STROBE checklist is found in Supplementary Table 7.

Study population and data sources

This study was conducted in the resident population of Qatar, applying methodology that was developed earlier to assess duration of protection of the BNT162b2¹³ and mRNA-1273¹⁴ coronavirus disease 2019 (COVID-19) vaccines in the same population during earlier acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection waves. COVID-19 laboratory testing, vaccination, clinical infection data, and demographic details were extracted from the national, federated SARS-CoV-2 databases that include, with no missing information, all polymerase chain reaction (PCR) testing, COVID-19 vaccinations, and COVID-19 hospitalizations and deaths in Qatar since the start of the pandemic.

Every PCR test conducted in Qatar is categorized based on symptoms and the reason for testing. Qatar has young, international demographics. Only 9% of Qatar's population is \geq 50 years of age and 89% are international expatriates from over 150 countries^{15,35}. The vast majority of individuals were vaccinated in Qatar, but if vaccinated elsewhere, those vaccinations were still registered in the health system at the port of entry upon arrival in Qatar.

Study design

Vaccine effectiveness against symptomatic SARS-CoV-2 Omicron (B.1.1.529)¹ infection during the large Omicron wave in Qatar, between December 23, 2021 and February 28, 2022, was estimated using the test-negative, case-control study design, a standard design for assessing vaccine effectiveness^{11,12,30,34}. A symptomatic Omicron infection was defined as a nasopharyngeal PCR-positive swab collected during the Omicron wave because of clinical suspicion of infection, i.e., symptoms indicative of a respiratory tract infection. Cases (BA.1, BA.2, or any-Omicron-subvariant infected persons) and controls (uninfected persons) were exact-matched by sex, 10-year age group, nationality, and calendar week of PCR test. The ratio of matching in each analysis was determined based on available cases and controls (Figure 2). Matching was implemented to control for established differences in the risk of exposure to SARS-CoV-2 infection in Qatar¹⁵⁻¹⁹.

Only the first PCR-positive test during the study was included for each case, whereas all PCRnegative tests during the study were included for each control. Controls included individuals with no record of a positive PCR or rapid-antigen test (RAT) during the study period. Only PCR tests conducted because of clinical suspicion of infection, i.e., symptoms indicative of a respiratory tract infection, were included in the analysis for cases and controls. All persons who received a vaccine other than BNT162b2 or mRNA-1273, or who received a different mix of vaccines, were excluded. These inclusion and exclusion criteria were implemented to minimize different types of potential bias based on earlier analyses in the same population^{13,14}. Every case (or control) that met the inclusion criteria and that could be matched to a control (case) was included in the analysis. COVID-19 vaccination status was ascertained at the time of the PCR test.

Vaccine effectiveness was also estimated against any severe, critical, or fatal COVID-19 infection due to Omicron, using the same methodology. Classification of COVID-19 case

24

severity (acute-care hospitalizations)⁹, criticality (intensive-care-unit hospitalizations)⁹, and fatality¹⁰ followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews (detailed description below). Each person who had a PCR-positive test result and COVID-19 hospital admission was subject to an infection severity assessment every three days until discharge or death, regardless of the hospital stay length or the time between the PCR-positive test and the final disease outcome. Individuals who progressed to severe⁹, critical⁹, or fatal¹⁰ COVID-19 between the PCR-positive test result and the end of the study were classified based on their worst outcome, starting with death, followed by critical disease, and then severe disease.

COVID-19 severity, criticality, and fatality classification

WHO defines severe COVID-19 as a SARS-CoV-2 infected individual with "oxygen saturation of <90% on room air, and/or respiratory rate of >30 breaths/minute in adults and children >5 years old (or \geq 60 breaths/minute in children <2 months old or \geq 50 breaths/minute in children 2–11 months old or \geq 40 breaths/minute in children 1–5 years old), and/or signs of severe respiratory distress (accessory muscle use and inability to complete full sentences, and, in children, very severe chest wall indrawing, grunting, central cyanosis, or presence of any other general danger signs)"⁹. Detailed criteria are in the WHO technical report⁹.

Critical COVID-19 is defined as a SARS-CoV-2 infected individual with "acute respiratory distress syndrome, sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy"⁹. Detailed criteria are in the WHO technical report⁹.

COVID-19 death is defined as "a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that

cannot be related to COVID-19 disease (e.g., trauma). There should be no period of complete recovery from COVID-19 between illness and death. A death due to COVID-19 may not be attributed to another disease (e.g., cancer) and should be counted independently of preexisting conditions that are suspected of triggering a severe course of COVID-19". Detailed criteria are in the WHO technical report¹⁰.

Laboratory methods and subvariant ascertainment

Real-time reverse-transcription polymerase chain reaction testing

Nasopharyngeal and/or oropharyngeal swabs were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: 1) extracted on KingFisher Flex (Thermo Fisher Scientific, USA), MGISP-960 (MGI, China), or ExiPrep 96 Lite (Bioneer, South Korea) followed by testing with real-time reverse-transcription PCR (RT-qPCR) using TaqPath COVID-19 Combo Kits (Thermo Fisher Scientific, USA) on an ABI 7500 FAST (Thermo Fisher Scientific, USA); 2) tested directly on the Cepheid GeneXpert system using the Xpert Xpress SARS-CoV-2 (Cepheid, USA); or 3) loaded directly into a Roche cobas 6800 system and assayed with the cobas SARS-CoV-2 Test (Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab gene regions. The second targets the viral N and E-gene regions, and the third targets the ORF1ab and E-gene regions.

All PCR testing was conducted at the Hamad Medical Corporation Central Laboratory or at the Sidra Medicine Laboratory, following standardized protocols.

Classification of infections by subvariant

Surveillance for SARS-CoV-2 variants in Qatar is mainly based on viral genome sequencing and multiplex RT-qPCR variant screening⁴² of random positive clinical samples^{2,13,30,32,43,44}, complemented by deep sequencing of wastewater samples^{2,45}.

A total of 315 random SARS-CoV-2-positive specimens collected between December 19, 2021 and January 22, 2022 were viral whole-genome sequenced on a Nanopore GridION sequencing device. Of these, 300 (95.2%) were confirmed as Omicron infections and 15 (4.8%) as Delta (B.1.617.2)¹ infections^{2,4,5}. Of 286 Omicron infections with confirmed subvariant status, 68 (23.8%) were BA.1 cases and 218 (76.2%) were BA.2 cases. No Delta case was detected in sequencing after January 8, 2022, nor were other variants.

Additionally, a total of 1,315 random SARS-CoV-2-positive specimens collected between December 22, 2021 and January 1, 2022 were RT-qPCR genotyped. The RT-qPCR genotyping identified 1 B.1.617.2-like Delta case, 366 BA.1-like Omicron cases, 898 BA.2-like Omicron cases, and 50 were undetermined cases where the genotype could not be assigned.

The accuracy of the RT-qPCR genotyping was verified against either Sanger sequencing of the receptor-binding domain (RBD) of SARS-CoV-2 surface glycoprotein (S) gene, or by viral whole-genome sequencing on a Nanopore GridION sequencing device. From 147 random SARS-CoV-2-positive specimens all collected in December of 2021, RT-qPCR genotyping was able to assign a genotype in 129 samples. The agreement between RT-qPCR genotyping and sequencing was 100% for Delta (n=82), 100% for Omicron BA.1 (n=18), and 93% for Omicron BA.2 (27 of 29 were correctly assigned to BA.2 and remaining 2 specimens genotyped as BA.2 were B.1.617.2 by sequencing). Of the remaining 18 specimens: 10 failed PCR amplification and sequencing, 8 could not be assigned a genotype by RT-qPCR (4 of 8 were B.1.617.2 by

sequencing, and the remaining 4 failed sequencing). All the variant RT-qPCR genotyping was conducted at the Sidra Medicine Laboratory following standardized protocols.

The large Omicron-wave exponential-growth phase in Qatar started on December 19, 2021 and peaked in mid-January, 2022²⁻⁵. The study duration coincided with the intense Omicron wave where Delta incidence was limited. Accordingly, any PCR-positive test during the study duration, between December 23, 2021 and February 28, 2022, was assumed to be an Omicron infection. Of note that the study duration started on December 23, 2021, and not on December 19, 2021, to minimize the occurrence of residual Delta incidence during the first few days of the Omicron wave.

Informed by the viral genome sequencing and the RT-qPCR genotyping, a SARS-CoV-2 infection with the BA.1 subvariant was proxied as an S-gene "target failure" (SGTF) case using the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, USA⁴⁶) that tests for the S-gene and is affected by the del69/70 mutation in the S-gene²². A SARS-CoV-2 infection with the BA.2 subvariant was proxied as a non-SGTF case using this TaqPath Kit.

Statistical analysis

Study samples were described using frequency distributions and measures of central tendency. Groups were compared using standardized mean differences (SMDs), defined as the difference in the mean of a covariate between groups, divided by the pooled standard deviation. SMD <0.1 indicated adequate matching⁴⁷. The odds ratio (and 95% confidence interval (CI)), comparing odds of vaccination among cases to that among controls, was estimated using conditional logistic regression factoring the matching in the study design. This analytical approach was implemented to reduce potential bias due to variation in epidemic phase^{11,48}, gradual vaccination roll-out^{11,48}, and other confounders^{15,17-19,49,50}. CIs did not factor multiplicity and should not be used to infer

definitive differences between study groups. Interactions were not examined. Vaccine effectiveness at different time frames and its associated 95% CI were then estimated using^{11,12}: Vaccine effectiveness = 1- odds ratio of vaccination among cases versus controls

Since we used a test-negative study design, some persons were tested, PCR-positive or PCRnegative, after one vaccine dose, but before the next vaccine dose. This allowed us to estimate effectiveness after each dose. In each time-since-vaccination stratum, for first, second, and third doses, we analyzed only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated (our reference group). Accordingly, the sample size for cases (and controls) varied in the different time-since-vaccination analyses. Effectiveness was estimated by one or more months in which one month was defined as 30 days, or by one or more weeks where one week was defined as 7 days.

Sensitivity analyses were conducted to assess the impact on effectiveness estimates of adjusting for documented prior infection and healthcare worker status in conditional logistic regression. With the majority of those unvaccinated being children or young persons, and therefore not necessarily representative of total population demographics, additional analyses were conducted to assess the impact of excluding children <12 years of age and individuals <20 years of age on effectiveness estimates. Statistical analyses were conducted in STATA/SE version 17.0^{51} .

Data availability

The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly for preservation of confidentiality of patient data. Access to this dataset is at the discretion of the Qatar Ministry of Public Health. Access to the dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its supplementary information.

Supplementary Appendix

Table of contents

Supplementary Table 1. Sensitivity analysis for the effectiveness of the BNT162b2 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, BA.2 Omicron infection, and any Omicron infection^{*}, adjusting for documented prior infection and health worker status in the conditional logistic regression.

Sub-studies [†]	-	Cases -positive)		ntrols negative)	Effectiveness in % (95% CI) [‡]					
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	(95 % CI) ¹					
Effectiveness against symptomatic BA.1 Omicron infection [§]										
Dose 1										
0-13 days after Dose 1 and no Dose 2	10	1,969	20	3,456	6.2 (-115.9 to 59.3)					
≥14 days after Dose 1 and no Dose 2	25	1,968	66	3,441	35.2 (-6.0 to 60.3)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	130	1,992	376	3,409	43.4 (28.8 to 55.1)					
4-6 months after Dose 2 and no Dose 3	502	2,004	941	3,506	3.6 (-10.6 to 15.9)					
\geq 7 months after Dose 2 and no Dose 3	3,570	2,060	6,007	3,947	-17.8 (-28.8 to -7.8)					
Dose 3 (booster dose)										
<1 month after Dose 3	180	2,008	622	3,339	58.3 (48.7 to 66.2)					
≥1 month after Dose 3	483	2,031	1,145	3,441	41.6 (31.0 to 50.6)					
Effectiveness against symptomatic BA.2 Om	icron infection	1								
Dose 1										
0-13 days after Dose 1 and no Dose 2	32	5,744	34	5,742	-2.1 (-67.3 to 37.7)					
≥14 days after Dose 1 and no Dose 2	64	5,774	99	5,739	35.2 (10.1 to 53.4)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	263	5,964	496	5,731	48.3 (39.0 to 56.2)					
4-6 months after Dose 2 and no Dose 3	1,203	5,924	1,318	5,809	9.1 (-0.1 to 17.5)					
\geq 7 months after Dose 2 and no Dose 3	8,003	5,840	7,762	6,081	-13.7 (-21.0 to -6.8)					
Dose 3 (booster dose)										
<1 month after Dose 3	709	6,038	1,034	5,713	44.6 (37.2 to 51.2)					
≥1 month after Dose 3	1,580	6,211	2,029	5,762	42.0 (35.6 to 47.8)					
Effectiveness against any symptomatic Omic	cron infection**		•							
Dose 1										
0-13 days after Dose 1 and no Dose 2	56	12,174	34	7,278	5.9 (-47.1 to 39.8)					
≥14 days after Dose 1 and no Dose 2	151	12,205	130	7,276	29.6 (9.6 to 45.2)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	585	12,623	599	7,309	44.8 (37.2 to 51.5)					
4-6 months after Dose 2 and no Dose 3	2,479	12,590	1,605	7,333	12.1 (5.0 to 18.7)					
\geq 7 months after Dose 2 and no Dose 3	16,435	12,564	9,073	7,637	-9.5 (-15.2 to -4.1)					
Dose 3 (booster dose)										
<1 month after Dose 3	1,326	12,777	1,300	7,275	49.9 (44.5 to 54.8)					
≥1 month after Dose 3	3,120	13,040	2,484	7,360	42.9 (37.7 to 47.6)					

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

*A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

[†]In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those

unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses.

[‡]Vaccine effectiveness was estimated using the test-negative, case-control study design^{1,2}.

[§]Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

Supplementary Table 2. Sensitivity analysis for the effectiveness of the mRNA-1273 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, BA.2 Omicron infection, and any Omicron infection^{*}, adjusting for documented prior infection and health worker status in the conditional logistic regression.

Sub-studies [†]	-	Cases (PCR-positive)		ntrols negative)	Effectiveness in % (95% CI) [‡]	
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	(95 % C1) ¹	
Effectiveness against symptomatic BA.1 Om	icron infection	ş				
Dose 1						
0-13 days after Dose 1 and no Dose 2	3	1,942	8	3,400	45.8 (-115.2 to 86.3)	
≥14 days after Dose 1 and no Dose 2	14	1,942	19	3,405	-40.1 (-191.7 to 32.7)	
Dose 2						
1-3 months after Dose 2 and no Dose 3	6	1,943	27	3,396	71.0 (22.6 to 89.1)	
4-6 months after Dose 2 and no Dose 3	289	1,976	667	3,377	27.1 (13.6 to 38.5)	
\geq 7 months after Dose 2 and no Dose 3	1,125	1,999	1,847	3,638	-16.8 (-31.1 to -4.1)	
Dose 3 (booster dose)						
<1 month after Dose 3	55	1,951	182	3,377	48.9 (27.9 to 63.8)	
≥1 month after Dose 3	36	1,953	102	3,396	46.0 (17.2 to 64.8)	
Effectiveness against symptomatic BA.2 Om	icron infection	1				
Dose 1						
0-13 days after Dose 1 and no Dose 2	8	5,651	10	5,649	3.0 (-151.5 to 62.6)	
≥14 days after Dose 1 and no Dose 2	31	5,645	27	5,649	-19.9 (-104.9 to 29.9)	
Dose 2						
1-3 months after Dose 2 and no Dose 3	26	5,664	40	5,650	39.7 (-1.2 to 64.1)	
4-6 months after Dose 2 and no Dose 3	989	5,756	1,059	5,686	6.0 (-4.9 to 15.8)	
\geq 7 months after Dose 2 and no Dose 3	2,917	5,627	2,686	5,858	-24.0 (-34.5 to -14.3)	
Dose 3 (booster dose)						
<1 month after Dose 3	164	5,727	250	5,641	36.7 (20.9 to 49.2)	
≥1 month after Dose 3	92	5,709	149	5,652	42.5 (23.6 to 56.7)	
Effectiveness against any symptomatic Omic	cron infection**					
Dose 1						
0-13 days after Dose 1	17	11,987	11	7,153	3.7 (-108.9 to 55.6)	
≥14 days after Dose 1 and no Dose 2	52	11,984	36	7,150	5.8 (-47.0 to 39.7)	
Dose 2						
1-3 months after Dose 2 and no Dose 3	47	12,014	51	7,151	39.7 (8.8 to 60.2)	
4-6 months after Dose 2 and no Dose 3	1,863	12,321	1,294	7,205	15.0 (7.0 to 22.3)	
\geq 7 months after Dose 2 and no Dose 3	5,820	12,144	3,112	7,374	-17.0 (-25.0 to -9.5)	
Dose 3 (booster dose)						
<1 month after Dose 3	323	12,156	321	7,148	40.8 (29.6 to 50.3)	
≥1 month after Dose 3	169	12,100	181	7,155	48.3 (34.7 to 59.1)	

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

*A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

[†]In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those

unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each timesince-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-sincevaccination analyses.

[‡]Vaccine effectiveness was estimated using the test-negative, case-control study design^{1,2}.

[§]Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

Supplementary Table 3. Sensitivity analysis for the effectiveness of the BNT162b2 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, BA.2 Omicron infection, and any Omicron infection^{*}, after excluding children <12 years of age.

Sub-studies [†]	-	Cases (PCR-positive)		ntrols negative)	Effectiveness in % (95% CI) [‡]					
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	(95 % CI) ¹					
Effectiveness against symptomatic BA.1 Omicron infection [§]										
Dose 1										
0-13 days after Dose 1 and no Dose 2	10	1,155	21	1,886	23.4 (-64.2 to 64.2)					
≥14 days after Dose 1 and no Dose 2	25	1,155	65	1,874	37.6 (0.3 to 60.9)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	127	1,181	351	1,858	45.1 (31.1 to 56.3)					
4-6 months after Dose 2 and no Dose 3	499	1,195	960	1,921	14.1 (1.3 to 25.2)					
\geq 7 months after Dose 2 and no Dose 3	3,564	1,251	6,001	2,380	-17.3 (-28.0 to -7.5)					
Dose 3 (booster dose)										
<1 month after Dose 3	181	1,192	637	1,754	61.0 (52.7 to 67.9)					
≥1 month after Dose 3	483	1,218	1,171	1,847	42.4 (33.2 to 50.4)					
Effectiveness against symptomatic BA.2 Om	icron infection	1								
Dose 1										
0-13 days after Dose 1 and no Dose 2	26	2,973	30	2,969	13.3 (-46.5 to 48.7)					
≥14 days after Dose 1 and no Dose 2	67	2,996	97	2,966	31.6 (6.2 to 50.1)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	257	3,199	488	2,968	51.4 (42.9 to 58.7)					
4-6 months after Dose 2 and no Dose 3	1,233	3,121	1,319	3,035	10.0 (0.8 to 18.3)					
\geq 7 months after Dose 2 and no Dose 3	8,001	3,064	7,742	3,323	-13.7 (-21.0 to -6.9)					
Dose 3 (booster dose)										
<1 month after Dose 3	705	3,265	1,057	2,913	44.5 (37.6 to 50.6)					
≥1 month after Dose 3	1,604	3,412	2,025	2,991	38.9 (32.7 to 44.5)					
Effectiveness against any symptomatic Omic	cron infection**		•							
Dose 1										
0-13 days after Dose 1 and no Dose 2	55	6,043	32	3,619	3.4 (-51.0 to 38.2)					
\geq 14 days after Dose 1 and no Dose 2	133	6,097	128	3,616	37.2 (19.4 to 51.1)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	616	6,466	588	3,656	43.8 (36.3 to 50.5)					
4-6 months after Dose 2 and no Dose 3	2,511	6,413	1,586	3,689	13.1 (6.0 to 19.7)					
\geq 7 months after Dose 2 and no Dose 3	16,552	6,302	9,025	4,014	-15.0 (-21.0 to -9.4)					
Dose 3 (booster dose)										
<1 month after Dose 3	1,323	6,648	1,278	3,634	48.0 (42.7 to 52.8)					
≥1 month after Dose 3	3,113	6,919	2,494	3,689	40.7 (35.8 to 45.3)					

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

*A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

¹In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

^{*}Vaccine effectiveness was estimated using the test-negative, case-control study design^{1,2}.

Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

Supplementary Table 4. Sensitivity analysis for the effectiveness of the mRNA-1273 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, BA.2 Omicron infection, and any Omicron infection^{*}, after excluding children <12 years of age.

Sub-studies [†]	es [†] Cases (PCR-positive)			ntrols negative)	Effectiveness in % (95% CI) [‡]					
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	(95 % CI) ¹					
Effectiveness against symptomatic BA.1 Omicron infection [§]										
Dose 1										
0-13 days after Dose 1 and no Dose 2	3	1,128	9	1,830	48.5 (-93.2 to 86.2)					
≥14 days after Dose 1 and no Dose 2	14	1,128	17	1,838	-29.5 (-168.7 to 37.6)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	6	1,129	30	1,824	70.1 (27.2 to 87.7)					
4-6 months after Dose 2 and no Dose 3	283	1,169	664	1,807	33.7 (21.6 to 44.0)					
\geq 7 months after Dose 2 and no Dose 3	1,125	1,184	1,830	2,074	-10.6 (-23.6 to 1.0)					
Dose 3 (booster dose)										
<1 month after Dose 3	54	1,139	184	1,807	52.0 (33.4 to 65.4)					
≥1 month after Dose 3	36	1,139	101	1,827	43.4 (15.5 to 62.1)					
Effectiveness against symptomatic BA.2 Om	icron infection	1								
Dose 1										
0-13 days after Dose 1 and no Dose 2	8	2,876	9	2,875	11.1 (-130.3 to 65.7)					
≥14 days after Dose 1 and no Dose 2	22	2,879	29	2,872	25.0 (-32.1 to 57.4)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	18	2,897	37	2,878	51.4 (14.6 to 72.3)					
4-6 months after Dose 2 and no Dose 3	945	3,022	1,059	2,908	16.1 (6.4 to 24.7)					
\geq 7 months after Dose 2 and no Dose 3	2,861	2,906	2,676	3,091	-16.0 (-25.6 to -7.3)					
Dose 3 (booster dose)										
<1 month after Dose 3	169	2,947	265	2,851	40.7 (26.9 to 51.9)					
≥1 month after Dose 3	84	2,941	153	2,872	47.9 (31.1 to 60.6)					
Effectiveness against any symptomatic Omic	cron infection**	•	•	· · · · · · · · · · · · · · · · · · ·						
Dose 1										
0-13 days after Dose 1 and no Dose 2	19	5,856	9	3,495	-17.6 (-161.4 to 47.1)					
≥14 days after Dose 1 and no Dose 2	40	5,868	36	3,490	28.9 (-12.3 to 54.9)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	43	5,890	46	3,497	45.2 (16.0 to 64.2)					
4-6 months after Dose 2 and no Dose 3	1,878	6,175	1,293	3,544	18.2 (10.6 to 25.1)					
\geq 7 months after Dose 2 and no Dose 3	5,832	6,001	3,107	3,716	-15.0 (-22.7 to -7.8)					
Dose 3 (booster dose)										
<1 month after Dose 3	327	6,027	320	3,490	44.4 (33.8 to 53.2)					
≥1 month after Dose 3	174	5,965	179	3,498	46.0 (32.4 to 56.9)					

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

*A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

¹In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

^{*}Vaccine effectiveness was estimated using the test-negative, case-control study design^{1,2}.

[§]Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

Supplementary Table 5. Sensitivity analysis for the effectiveness of the BNT162b2 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, BA.2 Omicron infection, and any Omicron infection^{*}, after excluding individuals <20 years of age.

Sub-studies [†]	Cases (PCR-positive)			ntrols negative)	Effectiveness in % (95% CI) [‡]					
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	(95 % CI) ¹					
Effectiveness against symptomatic BA.1 Omicron infection [§]										
Dose 1										
0-13 days after Dose 1 and no Dose 2	9	1,034	19	1,677	24.9 (-71.7 to 67.2)					
\geq 14 days after Dose 1 and no Dose 2	18	1,035	56	1,669	47.6 (10.0 to 69.5)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	87	1,050	259	1,648	48.1 (32.4 to 60.1)					
4-6 months after Dose 2 and no Dose 3	348	1,055	628	1,710	9.4 (-6.1 to 22.7)					
\geq 7 months after Dose 2 and no Dose 3	3,203	1,115	5,357	2,130	-18.4 (-29.9 to -7.9)					
Dose 3 (booster dose)										
<1 month after Dose 3	177	1,070	607	1,570	60.8 (52.0 to 68.0)					
≥1 month after Dose 3	480	1,096	1,141	1,661	40.0 (30.4 to 48.4)					
Effectiveness against symptomatic BA.2 Om	icron infection	1								
Dose 1										
0-13 days after Dose 1 and no Dose 2	26	2,674	26	2,674	0.0 (-72.2 to 41.9)					
\geq 14 days after Dose 1 and no Dose 2	58	2,699	88	2,669	35.7 (9.5 to 54.3)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	196	2,826	352	2,670	48.0 (37.4 to 56.8)					
4-6 months after Dose 2 and no Dose 3	955	2,701	908	2,748	-7.5 (-19.9 to 3.6)					
\geq 7 months after Dose 2 and no Dose 3	7,404	2,605	6,986	3,023	-27.0 (-35.7 to -18.8					
Dose 3 (booster dose)										
<1 month after Dose 3	724	2,937	1,028	2,633	41.5 (34.1 to 48.1)					
≥1 month after Dose 3	1,612	3,096	2,003	2,705	36.6 (30.2 to 42.4)					
Effectiveness against any symptomatic Omic	cron infection**									
Dose 1										
0-13 days after Dose 1 and no Dose 2	42	5,434	27	3,261	12.9 (-42.3 to 46.7)					
\geq 14 days after Dose 1 and no Dose 2	107	5,484	107	3,261	38.7 (19.3 to 53.5)					
Dose 2										
1-3 months after Dose 2 and no Dose 3	458	5,713	416	3,291	39.5 (30.0 to 47.7)					
4-6 months after Dose 2 and no Dose 3	1,860	5,561	1,065	3,317	-0.04 (-9.5 to 8.6)					
\geq 7 months after Dose 2 and no Dose 3	15,089	5,543	8,167	3,610	-19.6 (-26.2 to -13.3					
Dose 3 (booster dose)										
<1 month after Dose 3	1,316	6,012	1,270	3,266	47.4 (42.0 to 52.3)					
≥1 month after Dose 3	3,107	6,283	2,458	3,349	38.9 (33.9 to 43.6)					

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

*A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

¹In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

^{*}Vaccine effectiveness was estimated using the test-negative, case-control study design^{1,2}.

[§]Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

Supplementary Table 6. Sensitivity analysis for the effectiveness of the mRNA-1273 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, BA.2 Omicron infection, and any Omicron infection^{*}, after excluding individuals <20 years of age.

Sub-studies [†]	Cases (PCR-positive)		Controls (PCR-negative)		Effectiveness in % (95% CI) [‡]
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	(95 /0 CI) ²
Effectiveness against symptomatic BA.1 Om	icron infection	§			
Dose 1					
0-13 days after Dose 1 and no Dose 2	3	1,011	7	1,630	40.8 (-132.7 to 85.0)
≥14 days after Dose 1 and no Dose 2	14	1,011	17	1,637	-28.3 (-162.9 to 37.4)
Dose 2					
1-3 months after Dose 2 and no Dose 3	6	1,012	27	1,625	65.1 (14.9 to 85.7)
4-6 months after Dose 2 and no Dose 3	282	1,043	673	1,580	34.6 (22.8 to 44.6)
\geq 7 months after Dose 2 and no Dose 3	1,106	1,070	1,807	1,873	-9.7 (-22.8 to 1.9)
Dose 3 (booster dose)					
<1 month after Dose 3	54	1,021	178	1,610	50.6 (31.1 to 64.6)
≥1 month after Dose 3	37	1,021	91	1,636	32.5 (-0.4 to 54.6)
Effectiveness against symptomatic BA.2 Om	icron infection	9			
Dose 1					
0-13 days after Dose 1 and no Dose 2	8	2,593	7	2,594	-14.3 (-215.2 to 58.6)
\geq 14 days after Dose 1 and no Dose 2	28	2,591	27	2,592	-3.8 (-77.9 to 39.4)
Dose 2					
1-3 months after Dose 2 and no Dose 3	22	2,609	42	2,589	48.8 (13.3 to 69.7)
4-6 months after Dose 2 and no Dose 3	950	2,719	1,025	2,644	10.9 (0.7 to 20.1)
\geq 7 months after Dose 2 and no Dose 3	2,866	2,587	2,624	2,829	-21.9 (-32.0 to -12.6)
Dose 3 (booster dose)					
<1 month after Dose 3	167	2,665	255	2,577	37.9 (23.6 to 49.6)
≥1 month after Dose 3	93	2,648	150	2,591	41.6 (23.1 to 55.7)
Effectiveness against any symptomatic Omic	ron infection**		•	•	· · · · · ·
Dose 1					
0-13 days after Dose 1 and no Dose 2	17	5,266	8	3,151	-16.3 (-171.0 to 50.1)
\geq 14 days after Dose 1 and no Dose 2	47	5,271	31	3,151	7.2 (-47.3 to 41.5)
Dose 2					
1-3 months after Dose 2 and no Dose 3	46	5,294	47	3,150	42.8 (13.0 to 62.5)
4-6 months after Dose 2 and no Dose 3	1,877	5,551	1,270	3,203	16.0 (8.2 to 23.2)
\geq 7 months after Dose 2 and no Dose 3	5,763	5,402	3,076	3,357	-14.4 (-22.1 to -7.2)
Dose 3 (booster dose)			•		
<1 month after Dose 3	296	5,461	319	3,142	47.5 (37.7 to 55.8)
≥1 month after Dose 3	166	5,376	170	3,159	44.4 (30.2 to 55.8)

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

*A symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

¹In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

^{*}Vaccine effectiveness was estimated using the test-negative, case-control study design^{1,2}.

[§]Cases and controls were matched one-to-two by sex, 10-year age group, nationality, and calendar week of PCR test.

Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test.

	Item No	Recommendation	Main text page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Introduction			
Background/rati onale	2	Explain the scientific background and rationale for the investigation being reported	Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction
Methods	4		
Study design Setting	4 5	Present key elements of study design Describe the setting, locations, and relevant dates, including periods of	Methods ('Study design') Methods ('Study design') &
Setting	5	recruitment, exposure, follow-up, and data collection	Figure 2
Participants	6	(<i>a</i>) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	Methods ("Study population ar data sources' & 'Study design' & Figure 2
		(b) For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods ('Study design', 'COVID-19 severity, criticality and fatality classification', & 'Laboratory methods and subvariant ascertainment'), Tables 1 & 2, & Figure2
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Methods, Tables 1 & 2, & Figure2
Bias	9	Describe any efforts to address potential sources of bias	Methods ('Study design' & 'Statistical analysis')
Study size	10	Explain how the study size was arrived at	Figure 2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Methods ('Study design' & 'Statistical analysis') & Tables & 2
methods	12	(a) Describe all statistical methods, including those used to control for confounding	Methods ('Statistical analysis
		(b) Describe any methods used to examine subgroups and interactions	Methods ('Statistical analysis
		(c) Explain how missing data were addressed	NA, see Methods ('Study population and data sources')
		(d) If applicable, explain how matching of cases and controls was addressed	Methods ('Study design'& 'Statistical analysis')
		(\underline{e}) Describe any sensitivity analyses	Methods ('Statistical analysis'
Results Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 2 & Tables 1 & 2
		(b) Give reasons for non-participation at each stage	
Descriptive data	14	(c) Consider use of a flow diagram(a) Give characteristics of study participants (eg demographic, clinical, social)	Results ('Main analyses",
		and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of	paragraphs 1& 3) & Tables 1- NA, see Methods ('Study
Outcome data	15	interest Report numbers in each exposure category, or summary measures of exposure	population and data sources') Results ('Main analyses'', paragraphs 3-6), Figures 3 & 4
Main n 1	17		& Tables 3 & 4
Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results ('Main analyses", paragraphs 3-6), Figures 3 & 4 & Tables 3 & 4
		(b) Report category boundaries when continuous variables were categorized	Tables 1 & 2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Results ('Additional analyses' & Supp. Tables 1-6
Discussion			••
Key results	18	Summarise key results with reference to study objectives	Discussion, paragraphs 1 & 2

Supplementary Table 7. STROBE checklist for case-control studies.

Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion, paragraphs 3-6
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion, paragraphs 7 & 8
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion, paragraph 6
Other informatio	n		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Acknowledgements
A11 NTA			

Abbreviations: NA, not applicable; p. page; Supp. Supplementary.

References

- 1. Jackson, M.L. & Nelson, J.C. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine* **31**, 2165-2168 (2013).
- 2. Verani, J.R., *et al.* Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. *Vaccine* **35**, 3295-3302 (2017).